Ronald F. Tutrone, Jr., MD, FACS, summarizes two Phase III clinical trials testing the safety and efficacy of fexapotide, a novel treatment for benign prostatic hyperplasia (BPH).Read More
Ronald F. Tutrone, Jr., MD, FACS, CPI
Dr. Tutrone's clinical interests include treatment of urologic malignancies including kidney, bladder and prostate; laparoscopic treatment of renal and adrenal tumors; kidney stone treatment; urinary incontinence in men and women; and prostate disorders. He also performs the UroLift procedure for the treatment of BPH/enlarged prostate. He has been voted a "Top Doctor" by Baltimore magazine numerous times, and a "Super Doctor" for Urology in the Washington Post Magazine Washington, DC, Northern Virginia and Baltimore. Dr. Tutrone has authored numerous articles in the urology literature. He has been principal investigator in more than 200 clinical research trials. He is Chairman of the William E. Kalhert Endowment for Urological Research and Medical Director of Chesapeake Urology Research Associates.